Roche Completes Carmot Acquisition
Carmot Therapeutics announced its acquisition by Roche has been completed. Recall, Carmot and Roche entered into a definitive merger agreement for Roche to acquire Carmot for $2.7B upfront with the potential for $400M in milestone payments (previous FENIX insight). Below, FENIX provides brief highlights and insights on the acquisition.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.